A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

NCT03239340 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

154

Enrollment

INDUSTRY

Sponsor class

Conditions

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG: Osimertinib

Sponsor

AstraZeneca

Collaborators

[object Object]